|
|
Volumn 282, Issue 8, 1999, Pages 790-795
|
|
Are surrogate markers adequate to assess cardiovascular disease drugs?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANGINA PECTORIS AGENT;
ANTIARRHYTHMIC AGENT;
ANTICOAGULANT AGENT;
ANTIHYPERTENSIVE AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CARDIOVASCULAR AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
ENCAINIDE;
FLECAINIDE ACETATE;
INOTROPIC AGENT;
MORACIZINE;
NITRENDIPINE;
PHOSPHODIESTERASE INHIBITOR;
VASODILATOR AGENT;
ANTICOAGULANT THERAPY;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY DISEASE;
DRUG INDUCED DISEASE;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEART ARRHYTHMIA;
HEART FAILURE;
HUMAN;
HYPERTENSION;
HYPOKALEMIA;
MAJOR CLINICAL STUDY;
NOTE;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
STROKE;
|
|
EID: 0033603814
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.282.8.790 Document Type: Note |
|
Times cited : (316)
|
|
References (33)
|
